Oncogenuity

Executive Summary

Oncogenuity Inc. is a private biopharmaceutical company based in Cambridge, MA, dedicated to developing a novel class of oligonucleotide therapeutics termed ONCOlogues for genetically driven diseases. Founded in 2018 and operating as a partner of Fortress Biotech, the company holds an exclusive license from Columbia University for its core technology. Oncogenuity’s lead program targets the KRAS G12D mutation, one of the most common oncogenic drivers in cancers such as pancreatic, lung, and colorectal. The company’s platform also has potential applications against coronaviruses and other genetic disorders, though the primary focus remains oncology. By leveraging oligonucleotide-based approaches, Oncogenuity aims to address historically undruggable targets, offering a new modality to interfere with disease-causing gene expression. As a private entity with limited public disclosure, the company has not disclosed funding rounds, valuation, or clinical stage, suggesting it remains in preclinical or early translational development. Its affiliation with Fortress Biotech provides strategic support and potential pathways for advancement.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for KRAS G12D ONCOlogue35% success
• Q2 2026Partnership or Licensing Deal for Platform Technology40% success
• Q3 2026Preclinical Efficacy Data Publication50% success